Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder

Authors:

Abstract
Buprenorphine is a medication for opioid use disorder (MOUD) and a criterion standard treatment option for opioid use disorder (OUD). When taken consistently, buprenorphine reduces patient cravings for opioids, blunts the effects of opioids, and prevents opioid withdrawal.1-3 Previous research has found that at least 80% adherence to buprenorphine is needed to reduce the risk of relapse with opioids that can result in overdose,4 but issues such as poor treatment access and patient preferences can reduce adherence5-7; only 50% of patients adhere closely to their MOUD prescriptions.8 Low adherence to buprenorphine has previously been found to have severe consequences on patient health and spending.4,9-11 However, studies of MOUD nonadherence have primarily focused on nonadherent patient cohorts without looking at the immediate effects of gaps in treatment, variation across MOUD products and dosages, and have primarily considered Medicaid beneficiaries.9-11 Given the societal burden of the opioid epidemic,12 it is important to fill these knowledge gaps so health care professionals can better determine the short-term risks of nonadherence in patients and the relative benefits of different kinds of MOUD treatment and treatment intensity options.

This publication has 22 references indexed in Scilit: